Charles River Laboratories International, Inc. — Q1 2017 Form 10-Q
Business context and period: The company provides research models, discovery and safety assessment services, and other products and services supporting pharmaceutical and biotechnology research and development. This unaudited quarter ended April 1, 2017; the comparable quarter ended March 26, 2016. Amounts below are U.S. dollars.
Financial results
| Metric | Q1 2017 | Prior-year quarter |
|---|---|---|
| Revenue | $445.8 million | $354.9 million |
| Operating income | $69.5 million | $51.5 million |
| Net income attributable to common shareholders | $46.8 million | $37.1 million |
| Diluted EPS | $0.97 | $0.78 |
| Cash from operating activities | $34.0 million | $45.8 million |
| Capital expenditures | $15.9 million | $8.3 million |
- Revenue increased 25.6%; service revenue rose 38.0% and product revenue 5.3%. Foreign exchange reduced reported revenue growth by 2.1%.
- Operating margin was approximately 15.6%, compared with 14.5%; cost of services and products, excluding intangible amortization, was 61.5% of revenue versus 60.3%.
- Effective tax rate rose to 39.8% from 27.1%, primarily reflecting tax on the CDMO divestiture gain, partly offset by a $7.5 million share-based compensation tax benefit.
- Cash and cash equivalents were $131.5 million at quarter-end. Total debt was $1.174 billion, down from $1.213 billion at December 31, 2016; weighted-average debt interest rate was 2.07%. The company reported covenant compliance.
Material changes and notable items
- DSA revenue rose 44.2%, primarily reflecting the WIL Research acquisition ($57.5 million of revenue growth contribution), Agilux ($8.3 million), and increased legacy study volume. Manufacturing revenue increased 23.5%; RMS revenue increased 3.1%.
- The company sold WIL Research’s CDMO business on February 10, 2017, for $75.0 million in proceeds and recorded a $10.6 million gain. Management said the business was not optimized in the portfolio at its current scale and capital could be better deployed elsewhere.
- Other income included the divestiture gain, venture-capital investment gains, and gains on life-insurance investments; therefore, reported earnings included material non-operating gains.
- Operating cash flow declined despite higher earnings, principally due to changes in operating assets and liabilities and the noncash divestiture gain. Investing cash flow included $72.5 million of divestiture proceeds. Financing cash outflow included $48.2 million of treasury-stock purchases, including $32.1 million under the repurchase program.
- Goodwill decreased to $756.0 million, including $35.9 million removed with the CDMO sale. The company recorded $1.0 million in severance and transition costs during the quarter.
Outlook, risks and contingencies
- No specific revenue or earnings guidance is provided in the supplied filing text. Management stated that available funds, operating cash generation, and financing access should be sufficient for operations for the foreseeable future.
- Debt is primarily floating-rate; a 100-basis-point rate increase would raise annual pretax interest expense by approximately $11.7 million. A 10% strengthening of the U.S. dollar was estimated to reduce quarterly revenue by $17.2 million and operating income by $1.7 million, all else equal.
- The company had $25.1 million of unrecognized tax benefits and ongoing tax controversies; it estimated these benefits could decrease by up to $5.0 million over the next 12 months, partly depending on a pending ruling and competent-authority proceedings.
- A government-contract billing matter was settled in March 2017 for $1.8 million. The company stated that other pending lawsuits and proceedings were not expected to have a material adverse effect. It reported no material changes to the risk factors in its 2016 Form 10-K.
- The board increased the stock-repurchase authorization by $150 million on May 9, 2017, bringing the aggregate authorization to $1.3 billion. The filing cautions that forward-looking statements are subject to risks and actual results may differ materially.
Important facts for investors to verify
- How much of the reported growth reflects acquisitions versus underlying performance, especially in DSA and Manufacturing.
- Whether operating cash flow and working-capital trends improve, and whether margins recover from acquisition-related cost pressures.
- The sustainability of earnings excluding the CDMO gain and other investment-related gains, and the effect of the elevated tax rate.
- Debt repayment, floating-rate exposure, covenant headroom, and the amount of capital allocated to repurchases versus investment.
- Progress and outcomes related to tax matters, contingent consideration, and integration of acquired businesses.